Journal Article

III.2 Clinical morbidity and mortality in response to complement and leukocyte activation

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 17, issue suppl_7, pages 34-37
Published in print July 2002 | ISSN: 0931-0509
Published online July 2002 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/17.suppl_7.34
III.2 Clinical morbidity and mortality in response to complement and leukocyte activation

Show Summary Details

Preview

Guideline III.2

A. To achieve an improved clinical outcome regarding morbidity and mortality, the use of large pore/high‐flux biocompatible dialyzers should be preferred.

(Evidence level: B)

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.